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Abstract 
P-glycoprotein (P-gp), a well known efflux transporter in the blood brain barrier inhibits the uptake of substrate 
drugs into brain. The main aim of this study is to evaluate the effect of natural product based P-gp inhibitors on brain 
penetration of various CNS drugs which are P-gp substrates. In this study, we have evaluated the inhibitory effects 
of natural bioflavonoids (quercetin and silymarin) on P-gp by using digoxin and quinidine as model P-gp model 
substrate drugs. In vitro inhibitory effects were evaluated in Caco-2 cell lines using digoxin as a model drug and 
in vivo P-gp inhibiting effect was evaluated in mice model using quinidine as model drug. The accumulation and 
bidirectional transport of digoxin in Caco-2 cells was determined in presence and absence of quercetin and silymarin. 
Elacridar was used as standard P-gp inhibitor and used to compare the inhibitory effects of test compounds. The api-
cal to basolateral transport of digoxin was increased where as basolateral to apical transport of digoxin was decreased 
in concentration dependent manner in the presence of elacridar, quercetin and silymarin. After intravenous adminis-
tration of P-gp inhibitors, brain levels of quinidine were estimated using LC-MS method. Increased brain uptake was 
observed with quercetin (2.5-fold) and silymarin (3.5-fold). Though the brain penetration potential of P-gp substrates 
was lower than that observed in elacridar, both quercetin and silymarin improved plasma quinidine levels. Caco-2 
permeability studies and brain uptake indicate that both quercetin and silymarin can inhibit P-gp mediated efflux of 
drug into brain. Our results suggest that both silymarin and quercetin could potentially increase the brain distribution 
of co-administered drugs that are P-gp substrates.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
P-gp is an established factor in altering the pharma-
cokinetics of several drugs. Based on the studies of P-gp 
knockout mice and from the investigations of the effect 
of P-gp inhibitors on normal rodents and humans, it is 
known that P-gp is capable of decreasing the oral bio-
availability and brain distribution of drugs that are 
substrates of the P-gp efflux pump (Gallo et  al. 2003). 
Presence of P-gp expression at the apical surfaces of brain 
capillary endothelial cells and gut enterocytes has been 
determined to limit the penetration of P-gp substrates 
such as ivermectin and cyclosporin A in to the respec-
tive organs (Kwei et al. 1999). Later studies have revealed 
that P-gp is also present in many normal tissues includ-
ing liver, kidney etc. (Cordon-Cardo et  al. 1990). The 
generation of mice with disrupted P-gp knock out (KO) 
genes confirmed the significant protective pharmaco-
logical function of P-gp in the Blood Brain Barrier (BBB) 
(Schinkel et al. 1994, 1996). Entry of several drugs includ-
ing vinblastine, cyclosporine A, digoxin, dexamethasone 
into the brain has been regulated by P-gp (Schinkel et al. 
1995). In P-gp knockout mice, the penetration of vinblas-
tine into the brain was 7–46 folds higher when compared 
with wild type control (Van Asperen et al. 1996), encom-
pasing the role of P-gp in preventing the entry of its sub-
strates into the brain. A fraction of epileptic patients do 
Open Access
*Correspondence:  chandragodugu@gmail.com;  
chandra.niperhyd@gov.in 
1 Laboratory of Nano-Biology, Department of Regulatory Toxicology, 
National Institute of Pharmaceutical Education and Research (NIPER), 
Balanagar, Hyderabad, Telangana State 500037, India
Full list of author information is available at the end of the article
Page 2 of 9Ravikumar Reddy et al. SpringerPlus  (2016) 5:1618 
not respond to commonly prescribed antiepileptic drugs 
because of limited delivery to the brain. Studies suggest 
that the failure is because of over expression of ATP-
driven efflux pumps at the BBB (Löscher and Potschka 
2005). Escitalopram, a P-gp substrate, brain delivery was 
increased by P-gp inhibition using cyclosporin and vera-
pamil thereby resulted in enhanced antidepressant activ-
ity with threefold increased brain concentration (O’Brien 
et  al. 2013). Elacridar is a selective inhibitor for both 
P-gp and breast cancer resistance protein (BCRP) (Hyafil 
et al. 1993). There are number of drugs which have been 
reported as dual substrates for P-gp and BCRP (de Vries 
et  al. 2007). For the drugs to act in the CNS, sufficient 
drug delivery is pre requisite. So, the evaluation of drug 
candidate susceptibility for P-gp efflux is a crucial step in 
the development of novel therapeutics particularly in tar-
geting CNS. Silymarin, a bioflavonoid, is used for more 
than 2000 years to treat a range of liver and gallbladder 
disorders, including hepatitis, cirrhosis, and jaundice, 
and to protect the liver against poisoning from chemical 
and environmental toxins, including snake bites, insect 
stings, mushroom poisoning, and alcohol. The major 
active component is silibinin/silybin, which is hepato-
protective and possesses P-gp inhibiting property (Gazak 
et al. 2007). Silymarin potentiated the doxorubicin cyto-
toxicity in P-gp positive cells by inhibiting P-gp ATPase 
activity (Zhang and Morris 2003b). Similar results were 
observed in another study where silymarin in combina-
tion with biochanin A (an iso flavone from red clover 
extract) potentially increased the daunomycin cytotox-
icity and decreased the daunomycin efflux in resistant 
breast cancer cell line, MCF-7 ADR (Chung et al. 2005). 
The same combination increased the accumulation of 
digoxin and vinblastine in intestinal Caco-2 cells in a con-
centration dependent manner (Zhang and Morris 2003a).
Quercetin, another flavonoid, has multiple biological 
actions such as antioxidant, antiulcer, antiallergic and 
anticancer. Currently, it is in clinical trials for the treat-
ment of cancer and may be a promising drug of choice 
in future (Lakhanpal and Rai 2007). Quercetin decreased 
the resistance and increased the sensitivity of vinblastine 
and paclitaxel dose dependently in KBVI cells (human 
cervical carcinoma) which have P-gp expression (Limtr-
akul et  al. 2005). Cell lines of human pancreatic carci-
noma EPP85-181RDB (resistant to daunorubicin) and 
EPP85-181P (sensitive to daunorubicin) were treated 
with quercetin and found that quercetin altered the func-
tion of P-gp and decreased the expression of ABCB1 in 
EPP85-181RDB cell line. Through these findings querce-
tin was considered as potential modulator of P-gp (Bor-
ska et  al. 2010). P-gp substrates digoxin and quinidine 
were selected based on the physicochemical proper-
ties. Digoxin is a lipophilic drug (logP =  2.37) with low 
permeability (Caco-2, Papp 1.1 ×  10−6  cm/s) and quini-
dine is another lipophilic drug with high permeablity 
(Caco-2 Papp 20.4 × 10−6 cm/s) (Collett et al. 2004). The 
main aim of this study is to evaluate the effect of natu-
ral product based P-gp inhibitors on brain penetration of 
various CNS drugs which are P-gp substrates. Pharmaco-
logical inhibition of these efflux transporters prevents the 
inadequate distribution of drugs to the brain.
Methods
Materials
Caco-2 cells were procured from ATCC, USA. Tran-
swell 24-well inserts were procured from Corning (USA), 
Dulbecco’s modified eagles medium (DMEM) was from 
Gibco, 96 well plate, hydrophilic solvinert plates were 
purchased from Millipore, USA. Digoxin, quinidine, 
quercetin, silymarin and dimethyl sulfoxide (DMSO) 
were purchased from Sigma-Aldrich (USA) and all other 
chemicals were of HPLC grade.
Cell culture
Caco-2 cells were seeded in transwell poly carbonate 
inserts (6 well, 0.4 µm pore size, Corning co-star Co.) at 
70,000 cells per insert on the day of seeding. Cells were 
cultured in DMEM supplemented with 10 % fetal bovine 
serum and 1 % non essential amino acids (Gibco). All the 
cells were incubated at 37 °C in a humidified atmosphere 
with 5  % CO2 and 95  % air. For uptake studies, Caco-2 
cells were seeded on to 0.7  cm2 dishes at a density of 
approximately 70,000 cells per dish and used for experi-
ment. On the day of 21 TEER (Tran’s epithelial electri-
cal resistance) value was measured using Epithelial Volt 
ohmmeter (world precision instruments) and observed 
TEER value as more than 500 Ω cm2 that reflects conflu-
ent monolayer with tight junctions.
Animals
Male C57 mice weighing 30–35 g and of 6–8 weeks old 
were taken and the animal experiments were conducted 
in the animal research facility of Syngene International 
limited, Bengaluru, India. Animals were kept under 
a 12  h light/dark cycle with free access to water and 
food (Kumar et  al. 2014). Animal study protocols were 
approved by the Syngene International organisational 
animal ethics committee, Bengaluru, India.
Formulation
Dose volumes (5 mL/kg) of drugs were administered by 
i.v. route via tail vein injection. Quinidine formulation 
was prepared using 10  % Dimethylacetamide (DMAC), 
40 % Polyethyleneglycol (PEG-400), 20 % Water and 30 % 
of Hydroxypropyl β-cyclodextrin (HPβCD). The elacridar 
formulation contained 10 % DMAC, 40 % PEG-400, 30 % 
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HPβCD and 20 % water, quercetin and silymarin formu-
lations were prepared using 2 % N-methyl-2-pyrolidone, 
10 % ethanol, 30 % Polyethylene glycol 200 (PEG 200) and 
58 % saline.
Transport study
Transport experiments using Caco-2 cell monolayers 
were performed, Caco-2 cell monolayer’s with TEER 
value higher than 500  cm2 were washed with transport 
buffer (HBSS) containing 10  mM HEPES buffer. Trans-
port buffer containing quercetin and silymarin (50 and 
100  µM) solution was incubated for 30  min in apical 
chamber for apical to basal (AP to BL) assay and basal 
chamber for basal to apical (BL to AP) assay in a single 
plate. All solutions were prepared in dimethylsulphoxide 
(DMSO). The final concentration of DMSO in the wells 
was less than 0.1 %. After incubation, wells were washed 
with transport buffer. Transport buffer containing 
digoxin 10 µM, elacridar 5 µM + digoxin 10 µM, Silyma-
rin 50 µM + digoxin 10 µM, Silymarin 100 µM + digoxin 
10  µM, Quercetin 50  µM  +  digoxin 10  µM, Quercetin 
100  µM  +  digoxin 10  µM was added to apical cham-
ber for apical to basolateral assay and basal chamber for 
basolateral to apical assay, rest added with 2  % bovine 
serum albumin (BSA) solution for non-specific interac-
tion to the assay. Samples (200 µL) were taken from the 
receiver side at both chambers for analysis after incubat-
ing the cell monolayer’s at 37  °C for 30, 60 and 90  min 
and replaced with fresh transport buffer. The Caco-2 cell 
viability was studied in presence of silymarin and querce-
tin and found that the cell viability was not affected.
Brain penetration study of elacridar and quinidine
Mice were divided into two groups (n =  4). One group 
dosed with elacridar (5  mg/kg) i.v. 30  min prior to the 
dosing of quinidine (5 mg/kg) and the other group dosed 
with quinidine alone. Blood and brain samples were col-
lected at 0.5, 1, 3, 5 and 7 h post dose of probe substrate 
quinidine. Plasma and brain samples were collected and 
stored at −80 °C until analysis.
Brain penetration study of silymarin and quercetin 
with quinidine
Mice were divided into three groups (n  =  3–4). First 
group dosed with silymarin (20 mg/kg) i.v. 30 min prior 
to the dosing of quinidine (5 mg/kg). Second group dosed 
with quercetin (20 mg/kg) i.v. 30 min prior to the dosing 
of probe substrate quinidine and the other group dosed 
with probe substrate quinidine alone. Blood and brain 
samples were collected at 0.5, 1, 3, 5 and 7  h post dose 
of probe substrate. Blood was collected from mice under 
mild anaesthesia via tail vein and collected blood was 
centrifuged at 5000 rpm to separate plasma.
Sample preparation
After sacrificing the mice at different time points, brain 
was collected homogenised at 5× concentration with 
phosphate buffered saline using Bullet blender. Fifty µL 
of brain homogenate or plasma and 200 µL of internal 
standard (IS) in vehicle (70 % acetonitrile and 30 % water) 
were mixed in a 96-well hydrophilic solvinert plate. The 
acetonitrile mixtures were vortexed and centrifuged 
at 10,000  rpm for 10  min. Supernatant was collected in 
a 96 well plate and analysed by liquid chromatography 
with mass spectroscopy (LC-MS, QTRAP ABSCIEX API 
4000).
LC‑MS analysis
Standard curves were prepared by spiking a known 
concentration of quinidine into blank matrix and then 
processed according to the procedures described pre-
viously for each sample. Analysis was carried out using 
4000 QTRAP LC/MS/MS system with triple Quadruple 
mass spectrometer (AB SCIEX) equipped with an elec-
tron spray ionisation (ESI). The mass spectrometer was 
operated in the ESI positive ion mode and detection of 
ions were performed in the multiple reaction monitor-
ing (MRM) mode. The system was run in a gradient 
mode and flow rate was set at 0.67  mL/min for runt-
ime of 2.5 min (Table 1). The standard curves were lin-
ear and assay accuracy was found to be between 85 and 
115 %.
Pharmacokinetic analysis
Pharmacokinetic parameters (Cmax, t1/2, AUC, Tmax) were 
determined based on non compartmental approach using 
Phoenix winNonlin (Version 6.3).
Statistical analysis
The data obtained in this study were expressed as the 
mean of replicate determinations (n = 3–4) plus or minus 
the standard error mean (SEM). Statistical comparisons 
were made using T-test and one way analysis of variance 
Table 1 LC-MS conditions followed to  analyze quinidine 
and digoxin in plasma and cell culture samples
MRM multiple reaction monitoring, DP declustering potential, CE collision 
energy
Compound MRM transition DP CE Mobile phase and column
Digoxin 798.5/651.4 85 21 Mobile phase A
0.1 % acetonitrile in milli Q 
water
Mobile phase B
0.1 % Formic acid in Ace-
tonitrile
Column
Kinetex 50 mm (C18)
Quinidine 325.2/184.2 130 70
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(ANOVA). The intergroup variations were measured by 
Bonferroni’s Mulptiple comparison test using the soft-
ware Graph Pad Prism 5.0.
Results
Effect of elacridar on the transport of P‑gp substrate 
digoxin across Caco‑2 monolayers
Elacridar was standardised on the transport of digoxin 
across Caco-2 cell monolayer’s in both apical to baso-
lateral and basolateral to apical directions. As shown 
in Table  2, the apparent permeability coefficient for 
basolateral to apical transport of digoxin (PappB–A: 
1.8 × 10−6 cm/s) was higher than apical to basolateral 
(PappA–B: 5.18 × 10−8 cm/s) with a mean transport ratio 
(PappB–A/PappA–B) of 34.77, which shows the involvement 
of P-gp mediated efflux of digoxin in these cells. In 
presence of 5 µM elacridar (Table 2), the digoxin efflux 
of PappA–B was significantly increased (from 5.18 × 10−8 
to 1.52 ×  10−7  cm/s) whereas the PappB–A was signifi-
cantly decreased (from: 1.8 × 10−6 to 2.78 × 10−7 cm/s) 
resulting into a mean transport ratio of 1.83 (Table 2). 
All these results suggest that elacridar inhibited P-gp 
mediated cellular efflux and thus increase the apical to 
basolateral transport of digoxin and decrease the baso-
lateral to apical transport of digoxin, which indicates 
that elacridar as a complete P-gp inhibitor (Table  2; 
Fig. 1).
Effect of silymarin and quercetin on the transport of P‑gp 
substrate digoxin across Caco‑2 monolayers
As shown in Table  3, the apparent permeability coeffi-
cient for basolateral to apical transport of digoxin (PappB–
A: 1.8 × 10−6 cm/s) was higher than apical to basolateral 
(PappA–B: 5.18 × 10−8 cm/s) with a mean transport ratio 
(PappB–A/PappA–B) of 34.77, which shows the involve-
ment of P-gp mediated efflux of digoxin in these cells. 
In presence of 50 µM quercetin, the PappA–B was slightly 
increased (from 5.18  ×  10−8 to 5.93  ×  10−8  cm/s) 
whereas the PappB–A was slightly decreased (from 
1.8 × 10−6 to 1.23 × 10−6 cm/s) resulting a mean trans-
port ratio of 20.79. In presence of 100  µM quercetin 
(Table  3), the PappA–B was increased (from 5.18  ×  10−8 
to 1.04 × 10−7 cm/s) whereas the PappB–A was decreased 
(from 1.8 × 10−6 to 1.21 × 10−6 cm/s) resulting a mean 
transport ratio of 11.70. In presence of 50  µM silyma-
rin, the PappA–B was increased (from 5.18  ×  10−8 to 
5.51  ×  10−8  cm/s) whereas the PappB–A was decreased 
(from 1.8  ×  10−6 to 1.63  ×  10−6  cm/s) resulting in a 
mean transport ratio of 29.69 In presence of 100  µM 
silymarin, the PappA–B was increased (from 5.18  ×  10−8 
to 6.64 × 10−8 cm/s) whereas the PappB–A was decreased 
(from 1.8 × 10−6 to 1.42 × 10−6 cm/s) resulting an mean 
transport ratio of 21.35 (Table 3). The Caco-2 permeabil-
ity results indicate that both silymarin and quercetin can 
inhibit P-gp mediated cellular efflux and thus increase 
Table 2 Efflux ratio for digoxin in presence and absence of elacridar in the Caco-2 cell lines
Treatment AP‑BL transport BL‑AP transport Efflux ratio (BL‑AP/AP‑BL)
Digoxin10 µM 5.18E−08 1.80E−06 34.77 ± 6.7
Digoxin + Elacridar 5 µM 1.52E−07 2.79E−07 1.83 ± 0.08
Fig. 1 In vitro Caco-2 based P-gp inhibition study: a Efflux ratio of Digoxin and Digoxin with Elacridar, b Efflux ratio of Digoxin 10 µM alone, Digoxin 
in presence of Quercetin and Silymarin (50 and 100 µM). Each data point was represented as mean ± SEM (n = 3–4). *p < 0.05; **p < 0.01 and 
***p < 0.001 vs Quinidine alone groups. (D digoxin, E elacridar, Qr quercetin, S silymarin)
Page 5 of 9Ravikumar Reddy et al. SpringerPlus  (2016) 5:1618 
the AP to BL transport of digoxin and decrease the BL to 
AP transport of digoxin. Quercetin had stronger effects 
than silymarin when used at the same concentration, but 
neither of the flavonoids blocked P-gp completely at the 
tested concentrations of quercetin and silymarin at 50 
and 100  µM respectively. Both silymarin and quercetin 
showed concentration dependent effect on digoxin trans-
port as shown in the Table 3 and Fig. 1.
Effect of elacridar on plasma and brain pharmacokinetics 
and brain penetration of quinidine
Results of in vitro study motivated us to evaluate the effi-
cacy in vivo. Mouse mean plasma concentration versus 
time of i.v. dosed quinidine (5  mg/kg), in the presence 
and absence of elacridar (5  mg/kg i.v. 0.5  h pre-treat-
ment) were recorded. Pre-treatment of elacridar showed 
no significant difference in the plasma profile of quini-
dine, but a trend of increased t1/2 was observed whereas 
pre-treatment with elacridar resulted in significant dif-
ference in the brain profile of quinidine concentration 
with an increased Cmax and brain area under the curve 
(AUC) 0–7h (Table 4).
Effect of silymarin and quercetin on plasma and brain 
pharmacokinetics and brain penetration of quinidine
Pre-treatment of silymarin showed significant improve-
ment in plasma pharmacokinetic profile as well as brain 
penetration of quinidine with increased t1/2, Cmax and 
AUC. Pre-treatment of silymarin resulted in a maximum 
3.5-folds increase in Kp, brain of quinidine. Pre-treat-
ment of silymarin increased (AUC) 0–7h B/P by twofolds 
for quinidine (Fig. 2; Table 5). However, pre-treatment of 
quercetin showed no significant difference in plasma pro-
file, but a trend of increased t1/2 and Cmax was observed 
indicating an increased brain profile of quinidine with a 
trend of increased t1/2, Cmax and AUC. In contrast, pre-
treatment with quercetin resulted in 2.5-folds increase in 
Kp and brain (AUC) 0–7h B/P by twofold of quinidine. The 
respective representation of chromatograms depicting 
concentration of quinidine, quinidine  +  silymarin and 
quinidine + quercetin in both plasma and brain are men-
tioned in Fig. 3.
Discussion
Delivery to brain has ever been a major hurdle by virtue 
of blood brain barrier (BBB) that shields the brain from 
other body organs. Treatment of CNS disorders like epi-
lepsy, Alzheimer and brain tumors poses a great chal-
lenge due to sub effective concentration of drug reaching 
the target site. To achieve this goal, the researchers are 
working on novel strategies to improve the BBB distri-
bution of drugs in glioblastoma patients. The present 
study aims at improvement of brain delivery of quini-
dine, an FDA approved drug used for cerebral malaria 
and a well known P-gp substrate, by using natural fla-
vonoids quercetin and silymarin, which are well known 







Digoxin (10 µM) 5.18 1.80 34.77 ± 14.02
Digoxin + Quercetin (50 µM) 5.92 1.23 20.79 ± 0.13
Digoxin + Quercetin (100 µM) 10.4 1.22 11.70 ± 0.21
Digoxin + Silymarin (50 µM) 5.51 1.64 29.69 ± 3.10
Digoxin + Silymarin (100 µM) 6.64 1.42 21.35 ± 0.50
Table 4 Mean plasma and  brain pharmacokinetics parameters of  quinidine in  the presence and  absence of  elacridar 
after i.v. administration in mice
Parameters Plasma pharmacokinetics Brain pharmacokinetics
Quinidine (5 mg/kg) Quinidine with elacridar (5 mg/
kg)
Quinidine (5 mg/kg) Quinidine 
with elacridar 
(5 mg/kg)
Dose (mg/kg) 5 5 5 5
Half life (h) 1.43 2.15 1.50 0.88
Tmax (h) 0.66 0.50 0.80 0.83
Cmax (ng/mL) 209.16 185.87 115.40 2225.80
AUClast (h ng/mL) 496.40 459.80 211.40 4998.65
AUCINF_obs (h ng/mL) 513.40 523.83 251.20 5039.93
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P-gp inhibitors. Several lines of evidences have reported 
the role of both quercetin and silymarin as intestinal 
P-gp inhibitors. Significant improvement of relative bio-
availability was observed in study performed to enhance 
the oral bioavailability of paclitaxel and its formulation 
(Taxol) using silymarin and quercetin as P-gp inhibitor 
(Park et al. 2012; Choi et al. 2004). In consistent with the 
findings, in present study we used silymarin and querce-
tin to inhibit the P-gp at the BBB. The presence of P-gp 
efflux transporter at the BBB may restrict the entry of 
several P-gp substrates into the brain. The in vivo brain-
to-plasma concentration ratio of vincristine in ddY mice 
Fig. 2 In vivo P-gp inhibition study: a Mean plasma concentration, b Mean brain concentration, c Plasma AUC. d Brain AUC and e Brain to plasma 
ratio of Quinidine when combined with Quercetin and Silymarin. Each data point was represented as mean ± SEM (n = 3–4). *p < 0.05; **p < .0.01 
and ***p < 0.001 versus Quinidine alone groups
Table 5 Mean plasma and  brain pharmacokinetic parameters of  quinidine in  the presence and  absence of  silymarin 
and quercetin (10 mg/kg) after i.v. administration in mice
Parameters Plasma pharmacokinetics Brain pharmacokinetics
Quinidine With silymarin With quercetin Quinidine With silymarin With quercetin
Dose (mg/kg) 5 10 10 5 10 10
Half life (h) 1.43 1.73 1.86 1.50 1.95 1.91
Tmax (h) 0.66 0.50 0.50 0.80 0.50 0.83
Cmax (ng/mL) 209.16 364.48 244.80 115.40 301.60 235.73
AUClast (h ng/mL) 496.40 680.43 445.29 211.40 635.15 390.09
AUCINF_obs (h ng/mL) 513.40 704.07 463.55 251.20 682.40 405.64
Page 7 of 9Ravikumar Reddy et al. SpringerPlus  (2016) 5:1618 
was decreased by co-administration of 0.1 mg/kg querce-
tin, but increased by 1.0  mg/kg quercetin (Mitsunaga 
et  al. 2000). In current study, we used different drugs/
agents either as P-gp substrates (quinidine and digoxin) 
and P-gp inhibitors (elacridar, silymarin and quercetin) to 
evaluate the role of P-gp in brain distribution of drugs.
The model was established with standard P-gp inhibitor 
elacridar and was used to analyze the brain penetration 
of quinidine. In vitro Caco-2 cell line based permeability 
studies were performed by using digoxin as model P-gp 
substrate. The model P-gp subtrates, quinidine (high per-
meabililty) and digoxin (low permeability) were selected, 
which are lipophilic drugs and having Caco-2 Papp 
20.4  ×  10−6 and 1.1  ×  10−6  cm/s, respectively (Schin-
kel et  al. 1995). The effect of in  vivo P-gp inhibition of 
elacridar, silymarin and quercetin was calculated in terms 
of the increase in Kpbrain and brain to plasma AUC ratio 
in mice model. The in vitro P-gp inhibition was studied 
as efflux ratio of probe substrates in presence of selected 
inhibitors in Caco-2 cell line. Further, several studies had 
shown that P-gp efflux transporter contributes to the 
efflux of digoxin and quinidine across the BBB (Mayer 
et al. 1997).
We estimated P-gp inhibition of quercetin and silyma-
rin using Caco-2 permeability assay and compared those 
inhibitory effects with standard strong P-gp inhibitor 
elacridar. Both quercetin and silymarin produced con-
centration dependent P-gp inhibitory effects on Caco-2 
cell lines by increasing the apical to basolateral trans-
port of digoxin. We observed a significant change in the 
Fig. 3 Representative LC-MS chromatograms of Quinidine, a plasma concentration of Quinidine + Silymarin; b plasma concentration of Quini-
dine + Quercetin; c brain concentrations of Quinidine + Silymarin, and d brain concentrations of Quinidine + Quercetin after 2 h of administration. 
The left lane peaks are quinidine alone and right lane in presence of Silymarin/Quercetin. The shift in retention time in respective chromatograms 
indicates significant increase in the area under the curve in comparison to the quinidine alone peaks indicating effective P-gp inhibition in presence 
of drug treatment
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transport of digoxin with both the selected test inhibi-
tors at 50 and 100  µM concentrations for AP-to-BL as 
well as BL-to-AP transport. By using quercetin as a P-gp 
inhibitor similar type of results were published by Zhang 
et  al. (Zhang and Morris 2003a). In our study, querce-
tin appears to be more potent than silymarin in terms 
of digoxin efflux ratio on Caco-2 cell lines. Kpbrain of 
P-gp substrate quinidine was measured at different time 
point’s i.e. 0.5, 1, 2, 4 and 7 h in mice in the presence of 
elacridar, quercetin and silymarin. At 1 h time point, the 
fold increase in Kpbrain of P-gp substrate quinidine was 
found to be 22.5 in presence of elacridar, 3.5 in the pres-
ence of silymarin and 2.5 in the presence of quercetin. 
These results suggest that Kpbrain values varied with time 
of measurement and distribution kinetics of the com-
pound. A single time point measurement could mislead 
the evaluation of brain penetration of P-gp substrate. 
Therefore, in addition to Kpbrain we also determined the 
brain to plasma AUC ratio (B/P).
Quinidine showed a 3.5 and 2.5 folds increase in B/P 
ratio in combination with silymarin and quercetin, 
respectively in mice. Similar results were published by 
Xiao et  al. (2012) and Batrakova et  al. (2001). In pres-
ence of elacridar in mice, the B/P ratio of quinidine was 
increased by 22.5 fold over the control animals. Simi-
larly, Kallem et  al. (2012) reported a 38 fold increase in 
the B/P of quinidine in mice. The greater improvement of 
quinidine B/P with elacridar was compared with that of 
silymarin and quercetin. It was known that compounds 
with B/P greater than two in mdr1a/1b KO over the wild 
type mice (WT) are P-gp substrates (Liu et al. 2009). In 
the present study, animals treated with elacridar, silyma-
rin and quercetin also resulted in B/P ratio greater than 
two which confirms that selected inhibitors have sig-
nificant impact on the brain distribution of P-substrate 
drugs like quinidine. Moreover, findings of Youdim et 
al., prove that quercetin is able to effectively traverse the 
BBB based on the rate of uptake in in vitro (ECV304/C6 
coculture) and in situ (rat, cerebral hemispheres) models. 
Quercetin showed measurable in  vitro and in  situ BBB 
permeability. Furthermore, quercetin showed measur-
able quantities inside MDCK-MDR1 and immortalized 
rat brain endothelial cells (RBE4) proving the fact that it 
is able to bypass the over expressed efflux transporters, 
which is in line with our in vivo findings (Ishisaka et al. 
2011). In another study Mitsunaga et  al. (2000) showed 
the increase in uptake of [3H]vincristine across BBB 
upon treatment with 50  μM quercetin in  vitro in cul-
tured mouse brain capillary endothelial cells (MBEC4) 
and by 1.0  mg/kg quercetin in  vivo (ddY mice) which 
further conceptually proves our hypothesis. We also 
examined the effect of silymarin and quercetin on the 
pharmacokinetics of quinidine in mice and found an 
increase in half life and AUC compared with quinidine 
control.
Our study described that co-administration of sily-
marin and quercetin can improve drug delivery of P-gp 
substrate drugs in several brain disorders including 
glioblastoma and epilepsy. The P-gp inhibitory effects 
of quercetin and silymarin can be beneficial to deliver 
the drugs into brain where P-gp mediated efflux is the 
major barrier. Both, quercetin and silymarin have numer-
ous pharmacological activities and can synergise with 
many of such drugs that face the problem of poor brain 
penetration.
Conclusion
We conclude that concurrent use of quercetin and sily-
marin is safe in combination with the drugs which are 
P-gp substrates, to increase brain distribution. These 
compounds possess multiple pharmacological actions 
like anti-oxidant, anti-cancer, and anti-fibrotic activities, 
thus can be used synergistically for efficacious therapy 
with other conventional treatment regimens. Besides, the 
anti-oxidant nature of these drugs will nullify the oxida-
tive stress produced by the P-gp substrate drugs like dox-
orubicin etc which further adds to the significance of the 
use of anti-oxidants of plant origin.
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